All Updates

All Updates

icon
Filter
Partnerships
SkylineDx partners with NeraCare to co-develop Immunoprint
Precision Medicine
Apr 20, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Precision Medicine

Precision Medicine

Apr 20, 2023

SkylineDx partners with NeraCare to co-develop Immunoprint

Partnerships

  • Netherlands-based molecular diagnostic company SkylineDx has entered a strategic partnership with German lab developer NeraCare to co-develop a proteomic test called “Immunoprint” for survival prediction of melanoma patients.

  • Immunoprint by NeraCare will help life science companies bring melanoma therapies to market faster by identifying high-risk, early-stage melanoma patients. Both companies will work exclusively together to develop and license Immunoprint while leveraging SkylineDx's global network and discovery expertise, and will present validation data at the 2023 European Association of Dermato-Oncology congress.

  • SkylineDx is a biotech company specializing in molecular diagnostics for oncology and inflammatory diseases. SkylineDx's lead product is MMprofiler with SKY92, a clinical test that measures the activity of 92 cancer genes and is used to aid physicians in the prognosis of multiple myeloma. The company also has a R&D program called “Falcon” that aims to develop an array of diagnostic utilities for melanoma patients, providing physicians with the tools to optimize the clinical pathway of their patients. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.